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Abstract   21 
We have used three dimensional (3D) extrusion printing to manufacture a multi-active solid dosage 22 
form or so called polypill. This contains five compartmentalised drugs with two independently 23 
controlled and well-defined release profiles. This polypill demonstrates that complex medication 24 
regimes can be combined in a single personalised tablet. This could potentially improve adherence for 25 
those patients currently taking many separate tablets and also allow ready tailoring of a particular drug 26 
combination/drug release for the needs of an individual. The polypill here represents a cardiovascular 27 
treatment regime with the incorporation of an immediate release compartment with aspirin and 28 
hydrochlorothiazide and three sustained release compartments containing pravastatin, atenolol, and 29 
ramipril. X-ray powder diffraction (XRPD) and Attenuated Total Reflectance Fourier Transform 30 
Infrared Spectroscopy (ATR-FTIR) were used to assess drug-excipient interaction. The printed 31 
polypills were evaluated for drug release using USP dissolution testing. We found that the polypill 32 
showed the intended immediate and sustained release profiles based upon the active/excipient ratio 33 
used. 34 
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1. Introduction 42 
The use of multiple medications to control complex diseases such as cancer and heart diseases is an 43 
increasingly used therapeutic strategy [1, 2]. Each active pharmaceutical ingredient is traditionally 44 
administered via a separate dosage form [2]. This is inconvenient, can lead to errors in medication and 45 
presents significant patient compliance issues [2, 3]. Combining multiple actives into a single tablet 46 
with appropriate release profiles and doses (potentially optimised for individuals) is an attractive 47 
alternative [3-5].  48 
The term "polypill" refers to a tablet that is composed of a combination of several medicines [5], and 49 
has been previously studied as a concept to treat and prevent cardiovascular disease and high blood 50 
pressure [6-9]. This polypill (in fact a capsule) manufactured by Cadila Pharmaceuticals Limited 51 
under trade name of PolycapTM is the only polypill formulation commercially available [7, 8, 10]. 52 
Cardiovascular disease is the most common cause of death globally and requires managing as a 53 
chronic condition in many people during large portions of their lifetime [11]. Based on previous work, 54 
we suggest that additive manufacturing or 3D printing is potentially well suited to producing a 55 
multicomponent polypill formulation [4, 8, 9]. As an approach 3D printing also offers the opportunity 56 
to produce personalised medicines and is adaptable to a distributed manufacturing model [4]. The 57 
freedom to form specific geometries in comparison to the restrictions of traditional tableting via 58 
powder compression can be used to separate incompatible substances and to enable different release 59 
rates using shape and size as well as excipient manipulation [4, 12]. Here we have designed a 5-60 
component polypill based upon the currently available “polycap” commercial formulation with three 61 
sustained release compartments containing pravastatin, atenolol, and ramipril, which were physically 62 
separated by a hydrophobic cellulose acetate shell designed to act as a permeable carrier, and covered 63 
with an immediate release aspirin and hydrochlorothiazide compartment (Fig. 1.). Atenolol is a beta-64 
blocker agent which is used to treat hypertension and also prevent and/or treat heart attack [13]. 65 
Hydrochlorothiazide is a thiazide diuretic used to prevent absorption of too much salt and to treat 66 
oedema or fluid retention in individuals with congestive heart failure, kidney disorder, and liver 67 
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cirrhosis [14]. Ramipril is an angiotensin converting enzyme (ACE) used for treatment of 68 
hypertension and congestive heart failure which improves heart function after a heart attack [15]. 69 
Aspirin is an antiplatelet used to reduce the risk of blood clotting and reduce heart attacks or strokes 70 
[16]. Pravastatin is a 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors used 71 
to reduce blood cholesterol and triglycerides in hyperlipidaemic patients and lower rates of strokes 72 
and heart attacks [17].  73 
3D printing is a process used to fabricate 3D objects by laying down successive material layers in 74 
different shapes taken directly from a digital file [18]. There has been a significant recent growth in 75 
interest of 3D printing as a tool in pharmaceutics and personalised medicine [19-23]. For example, a 76 
heat based fused deposition modelling 3D printer (> 200 °C) has been used to extrude 5-77 
aminosalicylic acid (5-ASA, mesalazine), and 4-aminosalicylic acid (4-ASA) and prednisolone loaded 78 
poly (vinyl alcohol) (PVA) filaments and produce simple solid tablets [19, 24]. However, this 79 
approach would not be suitable generally due to the possibility of heat induced degradation of 80 
thermally sensitive drugs. Also, there are not many reports of printing a single drug formulation with 81 
multiple release mechanisms [4, 25]. Katstra et al. employed multi-steps 3D printing to deposit 82 
chlorphenaramin maleate (antihistamine used in the prevention of symptoms of allergic conditions 83 
such as rhinitis and urticaria) as a binder onto powdered excipients (the amount of drug deposited was 84 
5.45 mg) [25, 26]. However, issues such as ink bleeding, migration, and capillary effect due to 85 
drug/binder oversaturation are difficult to avoid for printing of larger drugs doses such as 500 mg of 86 
paracetamol or ibuprofen [25, 26]. Problems with this approach include long drying times (in excess 87 
of 50 hours) and high friability (> 1 %) of the resultant tablet [25, 26].  88 
To address the above mentioned issues of drug degradation and the complexity in published 3D 89 
printing processes we have employed a 3D extrusion system operated at room-temperature to 90 
manufacture a polypill capable of delivering the five drugs via two predictable release mechanisms. A 91 
hydrophobic cellulose acetate shell was first extruded then the active drugs atenolol, pravastatin, and 92 
ramipril were mixed with a hydrophilic matrix (HPMC) and extruded in to the segmented 93 
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compartments of cellulose acetate to form sustained release compartments. Aspirin and 94 
hydrochlorothiazide were mixed with a disintegrant; sodium starch glycolate and other excipients and 95 
extruded directly on the top of the sustained release compartments, to give an immediate release 96 
compartment. A series of raised dots were also printed onto the top of the tablet to facilitate 97 
identification of the formulation both visually and by touch, the composition of these was the same as 98 
the upper “immediate release” layer. The printed tablets were tested for drug release and drug-99 
excipients interaction using United States Pharmacopeia Convention (USP) Type I apparatus 100 
dissolution tester, X-Ray Powder Diffraction (XRPD), and Attenuated Total Reflectance Fourier 101 
Transform Infrared Spectroscopy (ATR-FTIR). 102 
2. Materials and methods 103 
2.1. Materials 104 
Ramipril and pravastatin sodium were supplied by Kemprotec Limited (Cumbria, UK). Atenolol, 105 
aspirin, and hydrochlorothiazide, polyvinylpyrrolidine (PVP) and lactose were supplied by Sigma–106 
Aldrich (Gillingham, UK). D-mannitol 99 % was purchased from VWR International Ltd. 107 
(Leicestershire, UK). Sodium starch glycolate (Primojel®) was kindly supplied as a gift from DFE 108 
Pharma. Hydroxypropyl methylcelloluse (HPMC K100M CR) (Methocel TM) was a gift from 109 
Colorcon®. Milli-Q water (resistivity 18.2 MΩ cm) was used for all formulations and solutions. All 110 
other reagents were of either HPLC or analytical grade. 111 
2.2. Methods  112 
2.2.1. Design of polypill 113 
A segmented tablet strategy was chosen to ensure that the actives were separated and could achieve 114 
the desired independent control of their release (Fig. 1). This concept provides flexibility in 115 
production of a 3D printed polypill with tunable drug release based on modifying the drug loading 116 
and excipient composition in the separate parts of the formulation. The dimensions of the polypill 117 
were selected according to the drug loading in respect of selected excipients (5.85 mm (height) × 6 118 
mm (radius)). The geometry of the polypill was designed using a 3D drawing package (BioCAD, 119 
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regenHU Villaz-St-Pierre, Switzerland). The combined drugs and their loadings in the polypill 120 
described in the experimental set up were adapted from clinical studies based on assessment of effect 121 
combination therapy on healthy middle aged individuals with one or more risk factors [8].  122 
 123 
Fig. 1. Schematic structural diagram of the polypill design, showing the aspirin and 124 
hydrochlorothiazide immediate release compartment and atenolol, pravastatin, and ramipril sustained 125 
release compartments. 126 
2.2.2. Materials for printing of polypill 127 
All powders were mixed using a mortar and pestle for 15 minutes. The printable paste used to form 128 
the barrier for the sustained release actives was prepared by mixing 3.15 g from the blended powder 129 
mixture; cellulose acetate (hydrophobic membrane/shell), D-mannitol (a filler), and polyethylene 130 
glycol (PEG 6000) (plasticizer) with 1.7 ml of the binder (acetone and dimethyl sulfoxide (DMSO)) 131 
until a smooth homogenous paste was achieved according to the formulae in Table 1. DMSO was 132 
used to increase the boiling point of the binder system and avoid nozzles blockage due to acetone 133 
evaporation (low boiling point) during the extrusion process. We used acetone/DMSO at a ratio of 3:1 134 
v/v. The volume of DMSO per tablet was approximately 28 µl, equivalent to 30.8 mg (3080 ppm) 135 
which is considered a very small volume/quantity in respect to DMSO human toxicity and was within 136 
the limit of the class 3 solvents (5000 ppm/day) which stated in ICH Harmonised Tripartite Guidance 137 
[27-31]. 138 
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Table 1. The weight percentage composition of various ingredients in cellulose acetate shell for 139 
sustained release formulation in feed stock. 140 
 141 
 142 
 143 
 144 
Powders of atenolol, pravastatin, and ramipril were separately blended using a mortar and pestle for 145 
15 min with the required excipients, to ensure homogeneous powder blend. Ultra-pure water was 146 
added to the powder and mixed as above method according to the formulae shown in Table 2. The 147 
immediate release layer was composed of aspirin and hydrochlorothiazide (active ingredients), 148 
sodium starch glycolate (disintegrant), and polyvinylpyrrolidone (PVP K30) (binder). The powder 149 
was blended and mixed with ultra-pure water to form a smooth and soft paste according to the 150 
formulae shown in Table 3. 151 
Table 2. The weight percentage composition of various ingredients in atenolol, pravastatin, and 152 
ramipril formulation feed stock for the sustained release compartments of the polypill. 153 
 154 
 155 
 156 
 157 
 158 
 159 
 160 
 161 
*ATEN = atenolol, **PRA = pravastatin, and ***RAM = ramipril 162 
Ingredients Function Coating  (% w/w) 
Cellulose acetate Hydrophobic shell 22.64 
D-mannitol Filler 62.26 
PEG (6000) Plasticizer 15.10 
Ingredients Function ATEN-HPMC* 
(15 % w/w) 
PRA-HPMC** 
(15 % w/w) 
RAM-HPMC*** 
(15 % w/w) 
Atenolol Active ingredient I 30.00 ---- ---- 
Pravastatin Active ingredient II ---- 20.00 ---- 
Ramipril Active ingredient III ---- ---- 15.00 
HPMC 2208 Hydrophilic matrix 15.00 15.00 15.00 
Lactose Filler 55.00 65.00 70.00 
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Table 3. The weight percentage composition of various ingredients in aspirin and hydrochlorothiazide 163 
immediate release formulation feed stock for the immediate-release compartment of the polypill. 164 
 165 
 166 
 167 
 168 
 169 
*ASA = acetylsalicylic acid (aspirin), HCT = hydrochlorothiazide, and IR = immediate release 170 
2.2.3. 3D based extrusion printing process  171 
All the pastes were loaded into separate ink cartridges for extrusion through a 500 µm print tip. The 172 
cellulose acetate shell was first extruded (no drying step needed), followed by extrusion of sustained 173 
release pastes inside the segmented cellulose acetate shell. The immediate release layer was then 174 
extruded on the top to cover the sustained release compartments, with the addition of identifying 175 
raised dots to illustrate the ability to provide integrated identification (visual and feel based) of the 176 
polypill (Fig. 2). The total printing time was 25 min followed by being placed in a vacuum dryer at 40 177 
°C for 24 hours for complete drying. 178 
 179 
Fig. 2. Photograph of regenHU 3D printer (left) [32], and image of multi-active tablet (right) (5.85 180 
mm  (height) × 6 mm (radius) composed of sustained release compartments (bottom), and immediate 181 
release dotted compartment (top). 182 
Ingredients Function ASA_HCT-IR* compartment 
Aspirin Active ingredient 28.62 
Hydrochlorothiazide Active ingredient 5.86 
Sodium starch glycolate  Disintegrant 55.18 
Polyvinylpyrollidine K30 Binder 10.34 
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2.2.4. Dissolution studies 183 
A HP Agilent 1050 HPLC equipped with an ACE C18-AR analytical column (100 mm x 4.6 mm) 184 
with 5 µm particle size was used to analyse dissolution release media for drug content. The auto-185 
sampler was set up to make 40 μl injections, every 25 minutes. The flow rate of the mobile phase was 186 
1 ml / min, the column temperature was 40 °C and the UV detection wavelength was 215 nm. The 187 
mobile phase (acetonitrile and water containing 0.1 % v/v of trifluoroacetic acid) was degassed and 188 
filtered through a 0.45 µm membrane filter. A mixture of actives (75 mg of aspirin, 12.5 mg of 189 
hydrochlorothiazide, 25 mg of atenolol, 20 mg of pravastatin, and 5 mg of ramipril) was dissolved in 190 
the dissolution medium and separated using the above HPLC method (Supplementary data, Appendix 191 
A, Fig. S.I. 1). 192 
In vitro drug release studies of the 3D printed polypill were performed using USP Type I apparatus 193 
(rotation speed at 50 rpm, 900 ml phosphate buffer, pH 6.8 containing 0.5 % of tween 80 (v/v) as the 194 
dissolution media at 37°C ± 0.5°C). 5.0 ml samples were withdrawn at 5, 15, 30, 60, 120, 240, 360, 195 
480, 600, 720 min. The samples were centrifuged and a small volume from the supernatant was drawn 196 
and filled into HPLC amber glass vials. The samples were kept at 4 °C (to decrease drug degradation) 197 
until tested. Drug dissolution studies were conducted in triplicate and the average of percentage of 198 
cumulative drug release as a function of time was determined. 199 
2.2.5. X-Ray Powder Diffraction (XRPD) 200 
The XRPD patterns of pure atenolol, pravastatin, ramipril, hydrochlorothiazide, and aspirin and their 201 
formulations (immediate and sustained release formulations) were obtained at room temperature using 202 
an X’Pert PRO (PANalytical, Almelo, Netherlands) setup in reflection mode using Cu Kα1 (lambda = 203 
1.54 Å) operating in Bragg–Brentano geometry. The generator voltage was set to 40 kV and the 204 
current to 40 mA and the samples were scanned over 2θ range of 5˚ until 30˚ in a step size of 0.026˚. 205 
 206 
 207 
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2.2.6. ATR-FTIR 208 
In order to investigate possible interactions between the actives and the selected excipients in their 209 
formulations, infrared spectra of pure active ingredients and their formulations were obtained using an 210 
ATR-FTIR (Agilent Cary 630 FTIR) spectrometer. 211 
3. Results and discussion 212 
3.1. In vitro drug dissolution 213 
Dissolution data from the polypill (Fig. 3) show that more than 75 % of the aspirin and 214 
hydrochlorothiazide were released within the first 30 minutes. This drug release is attributed to the 215 
inclusion of the disintegrant, sodium starch glycolate, which rapidly absorbs water and swells leading 216 
to rapid disintegration of this portion of the polypill and fast drug release. The same figure also shows 217 
that atenolol, pravastatin, and ramipril displayed sustained release over a period of 720 min as 218 
required; with 69 %, 81 %, and 66 % released respectively. This release is consistent with the effects 219 
of rapid hydration of the HPMC leading to a gel like formation and swelling to form a hydrophilic 220 
matrix that slows drug release and also to the presence of the permeable cellulose acetate shell which 221 
is expected to retard drug release [33-35].  222 
 223 
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Fig. 3. In vitro cumulative drug release profile of each drug from the five drug-loaded compartments 224 
of the polypill. 225 
These data clearly illustrate the potential to achieve different drug release profiles from the same 226 
tablet for different drugs. As the three drugs that require sustained release are in separate 227 
compartments this also clearly shows the opportunity that 3D printing provides to vary loading and 228 
the fine detail of each drug release.  229 
3.2. Physical characterisation of immediate and sustained release formulations 230 
3.2.1. XRPD 231 
XRPD data were collected on the pure as-received drugs before printing, and on the mixed 232 
formulations (immediate and sustained release formulations) containing the drugs after printing, in 233 
order to investigate any changes in physical form on printing (Figs. 4 and 5). All as-received materials 234 
exhibit multiple sharp Bragg peaks in their XRPD patterns related to their crystalline nature, except 235 
pravastatin which exhibits no sharp Bragg peaks indicating that it is exist in an amorphous state. The 236 
patterns for the crystalline materials match those reported in the Cambridge Structural Database (Fig. 237 
4) [36-39]. After formulation and printing, the Bragg peaks for ramipril, aspirin, hydrochlorothiazide, 238 
and atenolol are still present, with peaks also observed as expected from the excipients. For example, 239 
the appearance of a sharp peaks due to lactose are clearly visible at 20, 19, and 18 degrees 2-theta for 240 
the pravastatin, ramipril, and atenolol formulations, and the broad feature due to HPMC is visible at 241 
around 20 degrees 2-theta for the atenolol formulation. There is therefore no evidence of a change in 242 
physical form for the drugs in these three formulations. The situation is comparable for pravastatin, 243 
for which no obvious Bragg peaks from pravastatin are visible in both as-received and in the final 244 
formulation.  245 
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 246 
Fig. 4. XRPD patterns of the calculated and reference (measured) aspirin (top-left), 247 
hydrochlorothiazide (top-right), atenolol (bottom-left), and ramipril (bottom-right).  248 
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 249 
Fig. 5. XRPD patterns of Pra-HPMC (15 % w/w), pure pravastatin, lactose, and HPMC (top-left), 250 
Ram-HPMC (15 % w/w), pure ramipril, lactose, and HPMC (top-right), ASA-HCT-Formu, pure 251 
aspirin, pure hydrochlorothiazide, (polyvinylpyrrolidine) PVP k30, and sodium starch glycolate 252 
(bottom-left), and Aten-HPMC (15 % w/w), pure atenolol, lactose, and HPMC (bottom-right).  253 
3.2.2. ATR-FTIR 254 
The major diagnostic infrared peaks of the actives did not change within the formulations as 255 
compared to control spectra of the drugs alone, indicating that there were no detectable interactions 256 
between the drugs and the selected excipients (Fig 6). 257 
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 258 
Fig. 6. FTIR spectra of pure actives; aspirin and hydrochlorothiazide (top left), pravastatin (top right), 259 
atenolol (bottom left), and ramirpil (bottom right) and their formulations.  260 
It should be noted that all the polypills were printed to the expected size, mechanically stable, and can 261 
be handled readily without any loss of structural integrity. 262 
A relationship has been shown between heart disease and renal failure and various modifiable risk 263 
factors, such as hypertension, dyslipidaemia, and platelet capacity [40-43]. Therefore, patients over 55 264 
years old with one or more risk factors, including hypertension, obesity, and diabetes can benefit from 265 
a combined medications such as that demonstrated here that includes an antiplatelet, cholesterol and 266 
blood pressure lowering agents [44-46]. To use a combined medication approach successfully a 267 
number of challenges need to be considered, including; making the novel dosage form acceptable to 268 
health professionals and patients; formulation issues; additional cost; achieving regulatory approval; 269 
ensuring this becomes a first-line therapy (should be more effective and have no more side effects 270 
than drugs taken individually) [3]. The polypill demonstrated here addresses some of these issues, it is 271 
of an acceptable size and appearance for a patient, offers the prospect of increasing patient adherence 272 
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since only one tablet needs to be taken [4], and also should reduce risk of mistakes by patients who 273 
forget to take a certain medicine within a combination of different tablets [3]. Issues such as cost and 274 
regulatory approval are beyond the scope of the current work. 275 
Furthermore, application of 3D printing in pharmaceutics could offer a flexible tool to tailor the 276 
combined drug doses according to the patient’s needs. For example, control of tablet size and shape 277 
for children and elderly patient with difficulty handling tablets or swallowing, and printing ‘specials’ 278 
for tablets with allergies to certain excipients. We have demonstrated in this paper that a simple 279 
visual/tactile identifier can readily be added to 3D printed tablets to aid sight-compromised patient as 280 
well. 281 
4. Conclusions  282 
We have successfully demonstrated 3D extrusion printing of a novel complex geometry five-in-one 283 
polypill. We have also proved that the polypill is able to deliver five actives via two different and well 284 
defined release mechanisms: immediate and sustained release. The drugs were physically separated in 285 
the polypill to avoid incompatibility issues and allow maximum flexibility in manipulating the 286 
environment of each drug. XRPD and FTIR data were used to show that there was no detectable 287 
interaction between the drugs and the chosen excipients, and that our method of 3D printing did not 288 
lead to a detectable change in the physical form of the drugs (e.g. polymorphism, hydration etc). Such 289 
a combination of actives as used here has been shown to be important in prevention and treatment of 290 
cardiovascular diseases. The drugs combined as a polypill provide the prospect of improved 291 
adherence to such combination therapies due to the convenience of a single tablet and the potential to 292 
optimise and personalise dosages and release for each drug independently in such multi-drug dosage 293 
forms.  294 
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